Detalles de la búsqueda
1.
A simplified longitudinal model for the development of Type 2 Diabetes Mellitus.
J Theor Biol
; 587: 111822, 2024 Jun 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38589006
2.
Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes.
Diabetes Obes Metab
; 19(8): 1071-1077, 2017 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28191913
3.
Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.
Diabetes Obes Metab
; 19(11): 1521-1528, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28371155
4.
Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder.
BMC Psychiatry
; 8: 78, 2008 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18793440
5.
Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.
Hepatol Commun
; 2(5): 561-570, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29761171
6.
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Diabetes Care
; 39(7): 1241-9, 2016 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-26681715
7.
Coordinate regulation of L-arginine uptake and nitric oxide synthase activity in cultured endothelial cells.
Free Radic Biol Med
; 32(2): 122-31, 2002 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-11796200
8.
Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.
J Am Med Dir Assoc
; 5(1): 38-46, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-14706127
9.
Acute insulin response and beta-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks.
Diabetes Care
; 30(1): 157-8, 2007 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17192353
10.
Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Diabetes Care
; 40(6): 808, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28420698
11.
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Diabetes Care
; 39(11): e199-e200, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27926898
12.
Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder.
Ther Clin Risk Manag
; 4(4): 713-20, 2008 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19209252
13.
Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trials.
Am J Geriatr Psychiatry
; 14(1): 62-70, 2006 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-16407583
14.
Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.
J Clin Psychopharmacol
; 26(4): 405-8, 2006 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-16855460
Resultados
1 -
14
de 14
1
Próxima >
>>